Lisata Therapeutics’ (LSTA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a research report released on Thursday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock.

Lisata Therapeutics Trading Down 0.4 %

Shares of LSTA opened at $2.65 on Thursday. The firm has a fifty day moving average price of $3.02 and a 200-day moving average price of $2.72. The firm has a market capitalization of $22.02 million, a P/E ratio of -1.03 and a beta of 1.04. Lisata Therapeutics has a 12-month low of $1.95 and a 12-month high of $4.53.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.20. Analysts predict that Lisata Therapeutics will post -3.08 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lisata Therapeutics stock. BML Capital Management LLC increased its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 269,839 shares of the company’s stock after acquiring an additional 26,000 shares during the quarter. Lisata Therapeutics makes up about 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 24th largest position. BML Capital Management LLC owned approximately 3.31% of Lisata Therapeutics worth $737,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.